Benign Prostatic Hyperplasia Treatment by Transurethral Enucleation of the Prostate Using a 2-μm Laser

Abstract

This study investigates the efficacy of benign prostatic hyperplasia (BPH) treatment by prostate transurethral enucleation using a 2-μm laser. A total of 107 patients with BPH were treated by prostate transurethral enucleation using a RevoLix 2-μm laser surgery system. Bleeding volume, operation time, catheterization time, voiding situation, maximum urinary flow rate, and hospital stay were observed. The mean operation time was 74 min ± 12 min (range 45 to 150 min), the mean follow-up period was 2 to 6 months, the mean catheter time was 5 days, and the mean peak urinary flow rate increased from 6.3 ± 0.6 to 17.5 ± 1.5 mL/s. The International Prostate Symptom Score and quality of life significantly declined (p < 0.01). No significant differences were observed in the hemoglobin and blood electrolytes before and after operation. Prostate transurethral enucleation using a 2-μm laser is safe and efficient for BPH treatment.

Keywords: 2 μm lasers; Benign prostatic hyperplasia; Enucleation; Treatment.

Fig. 1

a Inside view of the prostatic urethra. The left- and right-side lobes (LSL, RSL) and verumontanum (V) are identified preoperatively. b Incisions from the bladder neck to verumontanum at the 5 to 7 o’clock positions. Enucleation from the leading edge of the verumontanum (Fib fiber). c The pale surgical capsule (SC) and supply vessels (SV). Laser is used to coagulate denuded supply vessels and hemorrhage spots and block the blood supply. d The right-side lobe (RSL) completely detached from the surgical capsule (BN bladder neck). e The left-side lobe (LSL) is detached from the surgical capsule at the bladder neck. f The urethral mucosa (UM) hanging around the urethral sphincter (UES) is cut with laser. g The view at the level of the urethral sphincter (UES), after a greater part of the bilateral lobes is detached. h The prostatic nodular hyperplasia (PNH) in the endoscopic field